RGNX - Why Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today? | Benzinga
Adverum Biotechnologies Inc (NASDAQ:ADVM) released preliminary safety and efficacy data from the ongoing LUNA Phase 2 trial in patients with wet age-related macular degeneration (AMD).
The LUNA trial is an ongoing double-masked, randomized, Phase 2 trial. 60 patients with wet AMD were enrolled equally across two dose cohorts, 2E11 and 6E10 vg/eye.
The study is designed to assess optimized prophylactic regimens, with patients receiving one and/or two locally administered corticosteroid regimens, with or without oral prednisone.
Among the 60 patients in the trial, no serious adverse events tied to the gene therapy were reported.
When looking at treatment burden ...